Pharmacomultiomics suggests new off-targets for targeted anti-cancer agents

Xuan Linh Mai; Chae-Young Lee; Eunbyul Cho; Sunghyouk Park; Hyuk Nam Kwon

doi:10.1016/j.jpha.2026.101580

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2026 > Accepted Manu

Xuan Linh Mai, Chae-Young Lee, Eunbyul Cho, Sunghyouk Park, Hyuk Nam Kwon. Pharmacomultiomics suggests new off-targets for targeted anti-cancer agents[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2026.101580

Citation:

Xuan Linh Mai, Chae-Young Lee, Eunbyul Cho, Sunghyouk Park, Hyuk Nam Kwon. Pharmacomultiomics suggests new off-targets for targeted anti-cancer agents[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2026.101580

Citation:

PDF( 2155 KB)

Pharmacomultiomics suggests new off-targets for targeted anti-cancer agents

doi: 10.1016/j.jpha.2026.101580

a. Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea;
b. Department of Biological Sciences, University of Ulsan, Ulsan, 44610, Republic of Korea;
c. Basic-Clinic Convergence Research Institute, University of Ulsan, Ulsan, 44610, Republic of Korea;
d. School of Biological Sciences, Seoul National University, Seoul, 08826, Republic of Korea

Funds:

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Republic of Korea (Grant No.: RS-2024-00448026).

Received Date: Oct. 11, 2025
Accepted Date: Feb. 07, 2026
Rev Recd Date: Feb. 03, 2026
Available Online: Feb. 10, 2026

Abstract

FullText(HTML)

References(5)

References

[1]	D. Sun, Gao W., Hu H., et al., Why 90% of clinical drug development fails and how to improve it, Acta Pharm. Sin. B 12 (2022) 3049−3062.
[2]	A. Lin, Giuliano C.J., Palladino A., et al., Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials, Sci. Transl. Med. 11 (2019), eaaw8412.
[3]	I.F. do Valle, Menichetti G., Simonetti G., et al., Network integration of multi-tumour omics data suggests novel targeting strategies, Nat. Commun. 9 (2018), 4514.
[4]	A. Suzuki, Onodera K., Matsui K., et al., Characterization of cancer omics and drug perturbations in panels of lung cancer cells, Sci. Rep. 9 (2019), 19529.
[5]	S. Ji, Feng L., Fu Z., et al., Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology, Sci. Transl. Med. 15 (2023), eadg3358.